These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 21224028)

  • 1. Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management.
    Van Buren PN; Toto R
    Adv Chronic Kidney Dis; 2011 Jan; 18(1):28-41. PubMed ID: 21224028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Common Drugs for Stabilization of Renal Function in the Progression of Diabetic Nephropathy and Their Relations with Hypertension Therapy.
    Wang Y; Wang C; Zhang X; Gu HF; Wu L
    Curr Diabetes Rev; 2018; 14(2):149-161. PubMed ID: 28201968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?
    Sternlicht H; Bakris GL
    Blood Purif; 2016; 41(1-3):139-43. PubMed ID: 26766168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of angiotensin receptor blockers in diabetic nephropathy.
    Sharma AM; Weir MR
    Postgrad Med; 2011 May; 123(3):109-21. PubMed ID: 21566421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.
    Fici F; Ari Bakir E; Ilkay Yüce E; Kanuncu S; Makel W; Tarim BA; Robles NR
    High Blood Press Cardiovasc Prev; 2020 Feb; 27(1):43-49. PubMed ID: 31916208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
    Jacobsen P; Rossing K; Parving HH
    Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The RAAS in the pathogenesis and treatment of diabetic nephropathy.
    Ruggenenti P; Cravedi P; Remuzzi G
    Nat Rev Nephrol; 2010 Jun; 6(6):319-30. PubMed ID: 20440277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renin-angiotensin-aldosterone system inhibition: overview of the therapeutic use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, and direct renin inhibitors.
    Mercier K; Smith H; Biederman J
    Prim Care; 2014 Dec; 41(4):765-78. PubMed ID: 25439533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
    Mavrakanas TA; Gariani K; Martin PY
    Eur J Intern Med; 2014 Feb; 25(2):173-6. PubMed ID: 24315413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation?
    Sarafidis PA; Ruilope LM
    Kidney Int; 2014 Mar; 85(3):536-46. PubMed ID: 24048382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current update in the management of diabetic nephropathy.
    Van Buren PN; Toto R
    Curr Diabetes Rev; 2013 Jan; 9(1):62-77. PubMed ID: 23167665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving microvascular outcomes in patients with diabetes through management of hypertension.
    McGill JB
    Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin receptor antagonists in patients with nephropathy due to type 2 diabetes.
    Eberhard R; Dikow R
    Ann Med; 2002; 34(7-8):507-13. PubMed ID: 12553490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021.
    Banerjee D; Winocour P; Chowdhury TA; De P; Wahba M; Montero R; Fogarty D; Frankel AH; Karalliedde J; Mark PB; Patel DC; Pokrajac A; Sharif A; Zac-Varghese S; Bain S; Dasgupta I;
    BMC Nephrol; 2022 Jan; 23(1):9. PubMed ID: 34979961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?
    de la Sierra A; Salazar J
    Adv Ther; 2011 Sep; 28(9):716-27. PubMed ID: 21809181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on Diabetic Nephropathy: Core Curriculum 2018.
    Umanath K; Lewis JB
    Am J Kidney Dis; 2018 Jun; 71(6):884-895. PubMed ID: 29398179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing cardiovascular events in high-risk patients: the challenge of managing hypertension in patients with diabetic renal disease.
    Toto RD
    J Clin Hypertens (Greenwich); 2007 Nov; 9(11 Suppl 4):16-25. PubMed ID: 17978603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Control of arterial pressure in diabetic nephropathy].
    Luño J; García de Vinuesa S
    Nefrologia; 2001; 21(3):240-5. PubMed ID: 11471304
    [No Abstract]   [Full Text] [Related]  

  • 20. Hypertension management in patients with diabetic nephropathy.
    McCall AL
    Curr Hypertens Rep; 2004 Aug; 6(4):272-9. PubMed ID: 15257861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.